Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 1;17:2201–2208. doi: 10.2147/OPTH.S424315

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Rush.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

A 76-year-old male with neovascular age-related macular degeneration and persistent macular fluid, despite 11 aflibercept injections during the previous 12 months and a total of 35 anti-VEGF treatments over the previous 3 years. The vertical line (green) in each image orients the reader to the same position in the macula between images. (A) Optical coherence tomography image at baseline demonstrates diffuse intraretinal macular fluid. Central macular thickness was 340 µm and Snellen visual acuity was 20/100. (B) Optical coherence tomography image of the same subject after switching from aflibercept to faricumab and receiving seven faricumab treatments over 12 months. Central macular thickness decreased to 268 µm and Snellen visual acuity improved to 20/60. The intraretinal macular edema is notably reduced from baseline, and now is only a trace amount. The subject was able to be extended to a 7-week treatment interval at the end of the 12-month study period.